Journal
DIABETES RESEARCH AND CLINICAL PRACTICE
Volume 172, Issue -, Pages -Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.diabres.2020.108631
Keywords
COVID-19; Sensory neuropathy; NerveCheck; Quantitative sensory testing; Diagnostic device; Diabetes
Categories
Ask authors/readers for more resources
In this study, four diabetic patients hospitalized with severe COVID-19 infection were found to have neuropathic symptoms and sensory dysfunction based on QST results, characterized by numbness in the feet. The results suggest that hypoxemia caused by COVID-19 infection may lead to neuropathic symptoms and sensory dysfunction.
Aims: To characterize the distribution and severity of sensory neuropathy using a portable quantitative sensory testing (QST) device in diabetic patients (DM) hospitalized with severe COVID-19 infection. Methods: Four patients with diabetes and severe SARS-CoV-2 requiring non-invasive ventilation for a protracted duration underwent clinical, laboratory and radiologic assessment and detailed evaluation of neuropathic symptoms, neurological assessment, QST on the dorsum of the foot and face using NerveCheck Master with assessment of taste and smell. Results: All four subjects developed neuropathic symptoms characterized by numbness in the feet with preserved reflexes. QST confirmed symmetrical abnormality of vibration and thermal thresholds in both lower limbs in all patients and an abnormal heat pain threshold on the face of two patients and altered taste and smell. Conclusions: Severe COVID-19 infection with hypoxemia is associated with neuropathic symptoms and widespread sensory dysfunction in patients with DM. (C) 2020 The Authors. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available